Solv's $45M Series C Targets 150 Million Americans in Urgent Care Push

Urgent care scheduling platform Solv closed a $45M Series C to scale its marketplace

Solv raised $45 million in Series C equity led by Acrew Capital and Corner Ventures, with participation from Benchmark and Greylock Partners. The company operates a B2B2C marketplace: clinics and urgent care networks pay for online scheduling, virtual visits, and patient acquisition tools, while patients discover providers through the Solv platform. Management stated the funding will support expansion to reach 150 million Americans over the next 12 months, up from its current footprint.

The round matters for enterprise buyers because it materially reduces financial viability risk. Health systems and payers evaluating urgent care telehealth partners face a persistent vendor-longevity question—particularly with platforms that require deep EHR integration and handle high-volume seasonal surges. A $45M raise backed by tier-one investors (Benchmark, Greylock) moves Solv from "promising mid-market option" to "credible national partner" in procurement conversations.

The competitive position shifts against Zocdoc and health system portals

Solv competes directly with Zocdoc in the scheduling-plus-telehealth category, and indirectly with employer-focused virtual care platforms like Teladoc and Included Health. Its focus on retail and urgent care workflows—same-day appointments, walk-in alternatives, episodic visits—differentiates it from traditional B2B telehealth suites designed for primary care or chronic condition management.

The $45M infusion changes three things for buyers comparing platforms:

First, network scale becomes a real advantage. Reaching 150 million Americans creates value for payers and large employers that want national coverage without stitching together regional urgent care contracts. Second, the capital supports deeper EHR integration roadmaps. Buyers should press Solv on specific timelines for Epic, Cerner, and athenahealth bidirectional sync—this funding makes those investments feasible. Third, pricing leverage shifts. A better-funded vendor has more room to negotiate enterprise deals (per-member-per-month or per-transaction models) to capture footprint, but also less pressure to discount aggressively.

For urgent care networks, the build-versus-buy calculation tilts toward buy. Building custom scheduling and telehealth on commodity video infrastructure (Zoom, Twilio) remains cheaper upfront, but Solv's funding velocity suggests the platform will outpace internal dev teams on feature breadth and compliance overhead (HIPAA, SOC 2, HITRUST).

Broader funding data clarifies vendor risk thresholds

Digital health startups raised $3 billion in Q1 2025 across 122 deals, up from $2.7 billion in Q1 2024. Telehealth and digital health platforms captured 34% of healthcare startup funding in that period. The top 60 telehealth startups have collectively raised $18.3 billion since 2015, with Series A rounds averaging $15 million.

These numbers set risk benchmarks. CIOs and payer CTOs should prefer vendors with at least Series B capital and total funding above $30-50 million for mission-critical infrastructure. Platforms below that threshold face higher execution risk on 24/7 support, compliance overhead, and regulatory changes like DEA tele-prescribing rules.

The funding environment also explains why deal counts dropped 45% in 2023 despite continued capital inflows. Investors consolidated around fewer, larger bets. For buyers, this means the telehealth vendor landscape is stabilizing—fewer early-stage entrants, more capital concentrated in proven platforms. That reduces the odds of surprise shutdowns or pivots mid-contract, but it also narrows the field of genuinely differentiated options.

What enterprise buyers should do now

Health systems evaluating urgent care telehealth partners should add Solv to RFP shortlists if geographic reach matters. Specifically, compare Solv's 150-million-American target against Zocdoc's current coverage and Teladoc's white-label urgent care offerings. Ask for roadmap specifics on EHR integration depth—bidirectional data sync, not just one-way feeds—and SLAs for uptime during seasonal demand spikes (flu, RSV).

Payers and employers negotiating telehealth contracts should revisit vendor financial viability criteria. Use the $15 million Series A average and $30-50 million total funding threshold as filters. If a platform falls short, require detailed financial disclosures or third-party audits before signing multi-year deals.

Finally, watch for pricing changes. Solv's expansion goal creates pressure to lock in large contracts quickly, which opens negotiation windows for per-member-per-month or volume-based pricing that undercuts incumbents. The trade-off: buyers commit to higher adoption targets in exchange for better unit economics. Make sure utilization forecasts account for patient preference inertia—most employees default to existing portals unless marketing pushes the new option aggressively.